Wave Life Sciences targets fat loss without sacrificing muscle
Wave Life Sciences has advanced its investigational therapy, WVE-007, into Phase 2a of the INLIGHT clinical trial. This therapy aims to reduce body fat while preserving muscle, differentiating itself from current GLP-1 drugs which can lead to muscle loss. The company is also exploring WVE-007's potential for infrequent dosing and its use in combination with or as a maintenance therapy after incretin-based medicines.
Wave Life Sciences Ltd. SEC Filing (Aug 17, 2026)
This article reports on an SEC filing by Wave Life Sciences Ltd. (WVE) on August 17, 2026, which is a Notice of Effectiveness with an effective date of August 14, 2026. The filing has a neutral impact and sentiment according to AI analysis. The article also provides recent news and other SEC filings related to Wave Life Sciences, including its redomiciliation to Delaware and insider trading activity.
Wave Life Sciences Inc (HAM:0VS) Stock Price, Trades & News
This page provides a detailed overview of Wave Life Sciences Inc (HAM:0VS) stock, including its current price (€4.96), market capitalization (€864.92M), and various financial metrics such as P/B ratio (2.17) and enterprise value. It highlights key financial strength, growth, momentum, liquidity, and profitability ranks, along with upcoming stock events and warnings about severe warning signs detected by GuruFocus. The company is described as a clinical-stage biotechnology firm focused on RNA medicines to treat rare and prevalent disorders.
Precision Trading with Wave Life Sciences Ltd. (WVE) Risk Zones
This article from Stock Traders Daily provides a detailed analysis of Wave Life Sciences Ltd. (WVE), highlighting weak sentiment across all horizons supporting a short bias. It outlines institutional trading strategies, including long, breakout, and short positions, with specific entry zones, targets, and stop losses. The analysis also features multi-timeframe signal analysis and AI-generated signals for WVE.
WAVE Life Sciences (NASDAQ:WVE) Director Adrian Rawcliffe Sells 12,700 Shares
WAVE Life Sciences (NASDAQ:WVE) Director Adrian Rawcliffe sold 12,700 shares of the company's stock for approximately $67,183. The sale occurred on August 12th when shares were trading at $5.29. Following the transaction, WVE shares fell to $5.20, near their 12-month low, and the company reported a quarterly loss and revenue weaker than analyst expectations, though analysts maintain a "Moderate Buy" rating with a target price of $22.53.
Insider Selling: WAVE Life Sciences (NASDAQ:WVE) Director Sells $42,070.00 in Stock
WAVE Life Sciences (NASDAQ:WVE) Director Heidi Wagner sold 7,000 shares of the company's stock for $42,070, reducing her position by 13.48%. The sale occurred amidst weak trading and quarterly results, with WVE shares near their 52-week low and the company reporting a loss and missing revenue estimates. Despite this, analysts maintain a "Moderate Buy" consensus with a significantly higher average target price.
Wave Life Sciences (WVE) director’s 3,864-share tax sale under 10b5-1 plan
Ken Takanashi, a director at Wave Life Sciences (WVE), sold 3,864 shares of common stock on August 11, 2026, at a weighted-average price of $6.01 per share. This sale was made under a Rule 10b5-1 trading plan solely to cover tax obligations arising from the vesting of restricted stock units. Following the transaction, Takanashi directly holds 20,079 shares and is associated with 9,606,408 indirect shares through SNBL USA and Shin Nippon Biomedical Laboratories, though he disclaims beneficial ownership beyond pecuniary interest.
Wave Life Sciences (WVE) Stock Looks Cheap After A 68% Fall But Expensive On Sales
Wave Life Sciences (WVE) stock has dropped 68.4% year-to-date, making it seem cheap, yet valuation checks still deem it expensive. The company's recent redomiciliation to Delaware aims to support access to U.S. capital markets, but its P/S ratio of 15.2x, significantly higher than the industry average of 5.0x, suggests overvaluation despite the price drop. The market appears to be highly optimistic about future revenue and execution, raising questions about whether the company can grow into its premium valuation.
Wave Life Sciences Ltd. SEC Filing (Aug 12, 2026)
This article reports on an SEC Form 144 filing by Wave Life Sciences Ltd. (WVE) on August 12, 2026. The filing indicates a proposed sale of 12,700 shares of common stock by an individual, acquired through Restricted Stock Units, with an aggregate market value of $64,071.50. The transaction involves Morgan Stanley Smith Barney LLC as the broker and is scheduled for August 12, 2026.
Watkins Advises Wave Life Sciences on Redomiciliation to Delaware
Latham & Watkins LLP advised Wave Life Sciences, Inc. on its redomiciliation process, changing the parent company from a Singapore entity to a Delaware corporation. This involved a scheme of arrangement under Singapore law, which received shareholder and High Court approvals and was completed on August 7, 2026. The Latham & Watkins team provided expertise across corporate, tax, executive compensation, employee benefits, and public company representation matters.
WAVE Life Sciences (NASDAQ:WVE) Hits New 52-Week Low - Here's What Happened
WAVE Life Sciences (NASDAQ:WVE) shares recently hit a new 52-week low of $5.01 after closing at $6.07, despite analysts maintaining a "Moderate Buy" rating with an average price target of $22.53. The stock decline follows the company reporting weaker-than-expected quarterly results, including a larger loss per share and significantly lower revenue than analyst estimates. Institutional investors have shown mixed activity, with some increasing their stakes while others adjusted positions.
Wave Life Sciences stock hits 52-week low at $5.01
Wave Life Sciences (WVE) stock has dropped to a 52-week low of $5.01, representing a 77% decline from its peak. Despite the significant downturn and recent disappointing Q2 2026 financial results, InvestingPro analysis suggests the stock is undervalued with a fair value of $6.36. The company recently redomiciled to Delaware and anticipates potential catalysts in late 2026, including clinical data and FDA discussions.
Wave Life Sciences Ltd. SEC Filing (Aug 11, 2026)
Wave Life Sciences Ltd. (WVE) filed a Form 144 with the SEC on August 11, 2026. This filing indicates a proposed sale of 7,000 common shares with an aggregate market value of $42,490.00, acquired through the exercise of stock options on the same day. The shares are intended to be sold on NASDAQ through Morgan Stanley Smith Barney LLC.
RA Capital group discloses 16.8% Wave Life Sciences (WVE) ownership after redomiciliation
RA Capital Management, L.P. and affiliated entities have disclosed a 16.8% beneficial ownership stake in Wave Life Sciences (WVE) following the company's redomiciliation on August 7, 2026. This ownership, totaling 34,314,406 shares, includes common stock held directly by their fund, shares issuable from Pre-Funded Warrants, and additional shares and options held by Dr. Peter Kolchinsky. The redomiciliation involved Wave Life Sciences, Inc. (Delaware) becoming the ultimate parent company, with Wave Life Sciences Ltd. (Singapore) becoming a wholly-owned subsidiary through a share exchange.
WAVE Life Sciences (NASDAQ:WVE) Stock Price Down 6.8% - Should You Sell?
WAVE Life Sciences (NASDAQ:WVE) shares recently dropped 6.8% to $5.66 after the company reported weaker-than-expected quarterly results, including a wider loss per share and lower revenue than projected. Despite the stock trading below its moving averages and remaining unprofitable, analysts maintain a "Moderate Buy" consensus rating with an average target price significantly higher than its current trading price. Institutional investors have also shown increased interest, adjusting their positions in the company.
Wave Life Sciences: WVE-007 and AATD programs are set for major clinical and regulatory milestones in the coming year
Wave Life Sciences' WVE-007 and AATD programs are expected to reach significant clinical and regulatory milestones within the next year. The company's strategic partnerships and strong financial standing are supporting ongoing clinical progress and a planned expansion into cardiometabolic indications. These updates were highlighted at a Bank of America SMID Cap Virtual Conference.
Wave Life Sciences Announces Completion of Redomiciliation to Delaware Corporation
Wave Life Sciences has successfully completed its redomiciliation from Singapore to a Delaware corporation, with the change taking effect after trading on August 7, 2026. All shares of the Singapore entity were exchanged for shares of the new Delaware corporation on a one-for-one basis, and the stock will continue to trade under the "WVE" symbol on NASDAQ. The company anticipates no material impact on its employees or operations and continues its focus on RNA medicines for various health conditions.
WAVE Life Sciences Ltd. (NASDAQ:WVE) Receives Consensus Rating of "Moderate Buy" from Brokerages
WAVE Life Sciences Ltd. (NASDAQ:WVE) has received a "Moderate Buy" consensus rating from 16 brokerages, with an average 12-month price target of $22.53. Despite this optimistic outlook, the company recently reported a quarterly loss and revenue that missed analyst expectations, along with a negative net margin. Institutional investors hold a significant portion of the company's stock, with several increasing their positions.
Wave Life Sciences Completes Redomiciliation From Singapore to Delaware
Wave Life Sciences (NASDAQ: WVE) has completed its redomiciliation from Singapore to Delaware, transferring its parent company jurisdiction while retaining its Nasdaq ticker and Cambridge headquarters. This corporate restructuring, effective August 7, 2026, involved a one-for-one share exchange and is not expected to materially impact employees or daily business operations. The company will continue its focus on developing RNA medicines for various disorders, maintaining operational continuity during this transition.
Wave Life Sciences Keeps WVE Ticker After Delaware Parent Move
Wave Life Sciences (NASDAQ: WVE) has completed its redomiciliation process, changing its parent company from a Singapore entity to a Delaware corporation. This was achieved through a scheme of arrangement where existing Singapore shares were exchanged one-for-one for newly issued common shares of the Delaware corporation. The company's equity will continue to trade under the ticker symbol "WVE" on NASDAQ, and no material impact on employees or day-to-day business is anticipated.
Analysts Just Made A Major Revision To Their Wave Life Sciences Ltd. (NASDAQ:WVE) Revenue Forecasts
Analysts have significantly downgraded their revenue forecasts for Wave Life Sciences Ltd. (NASDAQ:WVE) for 2026, now expecting a 20% decline in sales to US$52m, while losses per share are projected to remain steady at US$1.14. This revision has led to a 13% drop in the consensus price target to US$19.06, reflecting concerns about a weaker revenue outlook and anticipated slower growth compared to the industry average. Investors are advised to consider the long-term earnings trajectory and insider ownership, available through Simply Wall St's free analysis.
Wave Life Sciences Announces Completion of Redomiciliation to Delaware
Wave Life Sciences, Inc. announced the completion of its redomiciliation process, changing its parent company from a Singapore entity to a Delaware corporation. This change, which involved the exchange of ordinary shares for new common stock, occurred after the close of trading on August 7, 2026, and the common stock began trading on NASDAQ under the symbol "WVE" on August 10, 2026. The company does not expect any material impact on its operations or employees as a result of this redomiciliation.
Wave Life Sciences (WVE) files prospectus for 7.1M-share stockholder resale
Wave Life Sciences Inc. has filed a post-effective amendment to its existing shelf registration, reflecting its redomiciliation from Singapore to Delaware and adopting the prior Form S-3. The amendment covers the resale of up to 7,072,781 shares of common stock by existing selling stockholders, with Wave Life Sciences not receiving any proceeds from these sales. The shares were originally issued in various private financings, debt exchanges, and the company's 2015 IPO, and were converted one-for-one into Delaware common stock on August 7, 2026.
Wave Life Sciences Ltd. SEC Filing (Aug 7, 2026)
Wave Life Sciences Ltd. (WVE) filed a Form 15-12G with the SEC on August 7, 2026, certifying the termination of its registration under Section 12(g) of the Securities Exchange Act of 1934 or the suspension of its duty to file reports under Sections 13 and 15(d). The company's principal executive offices are located in Singapore, and its ordinary shares are the class of securities covered by this filing. This action indicates the company is ceasing to be a reporting company under certain SEC regulations.
Wave Life Sciences Announces Expected Completion Date for Redomiciliation to Delaware
Wave Life Sciences announced that its proposed redomiciliation to the United States, via a scheme of arrangement under Singaporean law, is expected to become effective after the close of trading on Friday, August 7, 2026. This follows shareholder and High Court of Singapore approvals. The company plans to file with the SEC after the market close on the same day the redomiciliation becomes effective.
Wave Life Sciences redomiciliation to U.S. set for Friday By Investing.com
Wave Life Sciences (NASDAQ:WVE) is set to complete its redomiciliation from Singapore to the United States on Friday, August 7, 2026, after the close of trading. The biotechnology company, which develops RNA medicines for various diseases, received shareholder and Singapore High Court approval for the move. This change will make its parent company a Delaware corporation and is expected to become effective upon filing with Singapore's Accounting and Corporate Regulatory Authority.
Singapore High Court approves scheme for Wave Life Sciences’ Delaware move
Wave Life Sciences (NASDAQ: WVE) announced the Singapore High Court has approved its Scheme of Arrangement for redomiciliation to the United States. The move is expected to become effective after the close of trading on August 7, 2026, upon filing the court order with Singapore's Accounting and Corporate Regulatory Authority. Following this, Wave plans to make necessary filings with the U.S. Securities and Exchange Commission on the same day.
Wave Life Sciences Announces Expected Completion Date for Redomiciliation to Delaware
Wave Life Sciences announced that its redomiciliation to Delaware, previously approved by shareholders and the High Court of the Republic of Singapore, is expected to become effective after market close on Friday, August 7, 2026. This change involves moving the parent company from Singapore to a Delaware corporation. The company will file necessary documents with the SEC following the effectiveness of the redomiciliation.
Wave Life Sciences to Present at Upcoming Investor Conferences
Wave Life Sciences will present at two upcoming investor conferences in August 2026. Paul Bolno, MD, MBA, President and CEO, will participate in analyst-led fireside chats at the BofA Securities 2026 SMID Cap Executive Insights Event and the Canaccord Genuity 46th Annual Growth Conference. Live webcasts and replays of these presentations will be available on the company's investor relations website.
Wave Life Sciences to Present at Upcoming Investor Conferences
Wave Life Sciences announced that its management team will participate in two investor conferences in August 2026. Paul Bolno, President and CEO, will participate in analyst-led fireside chats at the BofA Securities 2026 SMID Cap Executive Insights Event and the Canaccord Genuity 46th Annual Growth Conference. Webcasts of these presentations will be available on the company's website.
Wave Life Sciences to Present at Upcoming Investor Conferences
Wave Life Sciences announced that its management team will participate in two upcoming investor conferences in August 2026. Paul Bolno, MD, MBA, President and CEO, is scheduled to engage in analyst-led fireside chats at both the BofA Securities 2026 SMID Cap Executive Insights Event and the Canaccord Genuity 46th Annual Growth Conference. Live webcasts and replays will be available on the company's investor relations website.
Wave Life Sciences (WVE) Q2 2026 Earnings Call Transcript
Wave Life Sciences discussed its Q2 2026 financial results and pipeline progress, particularly for WVE-007 in obesity, WVE-006 for AATD, and WVE-008 for PNPLA3 liver disease. The company highlighted WVE-007's potential for fat loss without muscle degradation, WVE-006's progress toward a potential accelerated approval pathway with the FDA, and WVE-008's RNA editing approach for liver disease. Increased R&D and G&A expenses were reported, with a cash runway extending into Q3 2028.
Wave Life Sciences (WVE) Is Down 5.2% After Wider Q2 Losses And RNA Editing Updates - What's Changed
Wave Life Sciences reported wider Q2 2026 losses and significantly lower sales but highlighted progress in its RNA editing programs, particularly with obesity candidate WVE-007 and AATD therapy WVE-006. The company's investment narrative hinges on these platforms justifying ongoing losses, with WVE-006's potential accelerated approval pathway being a key near-term catalyst. Despite financial setbacks, promising clinical data for WVE-006 continues to support its value as a significant program.
Wave Life Sciences (WVE) Is Down 5.2% After Wider Q2 Losses And RNA Editing Updates - What's Changed
Wave Life Sciences reported wider Q2 2026 losses of US$69.36 million and lower sales of US$2.27 million, causing its stock to drop 5.2%. Despite the financial setbacks, the company highlighted positive progress in its RNA editing and RNAi programs, particularly for its AATD therapy WVE-006, which is preparing for an FDA meeting regarding accelerated approval. This juxtaposition of increased losses and promising clinical developments shapes the company's investment narrative, with WVE-006 being a key near-term catalyst.
Wave Life Sciences: Obesity Drug Advances To Phase 2 With Potential For Fat Loss Without Muscle Loss
Wave Life Sciences has initiated Phase 2a of its INLIGHT clinical trial for WVE-007, an investigational obesity treatment designed to reduce body fat while preserving muscle mass. This drug aims to offer a differentiated approach compared to existing incretin-based medicines, with potential for less frequent dosing and broader cardiometabolic benefits. The company also continues to advance other RNA-based therapies for alpha-1 antitrypsin deficiency and liver disease, while reporting increased R&D expenses and a widened net loss for the second quarter.
Wave Life Sciences (WVE) Stock Sinks As Losses Deepen And Revenue Dries Up
Wave Life Sciences (WVE) stock dropped 4.3% after reporting Q2 2026 earnings with significantly widened losses and reduced collaboration revenue. The company recorded a net loss of US$69.4 million on US$2.3 million in revenue, a substantial decrease from the prior year. While bulls point to an extended cash runway into Q3 2028 and ongoing clinical trials for their RNA medicines, bears highlight concentration risk, continued heavy burn rate, and the uncertainty of future funding and clinical milestones.
Wave Life Sciences (WVE) Stock Sinks As Losses Deepen And Revenue Dries Up
Wave Life Sciences (WVE) experienced a 4.3% stock drop following its Q2 2026 earnings report, which revealed a net loss of US$69.4 million and a significant 73.9% decline in collaboration revenue. While the company's "bull case" highlights its progress in RNA medicine development and sufficient cash to fund operations until Q3 2028, the "bear case" points to widening losses, dilution risk, and execution pressures, particularly given the reliance on binary clinical trial outcomes and the absence of a clear path to profitability.
Wave Life Sciences (WVE) Stock Sinks As Losses Deepen And Revenue Dries Up
Wave Life Sciences (WVE) stock dropped 4.3% following Q2 2026 earnings, reporting a net loss of US$69.4 million on only US$2.3 million in collaboration revenue. The company's losses have deepened significantly, with trailing 12-month net losses reaching US$202.5 million, while revenue has fallen substantially year-over-year. Despite concerns about the burn rate and dilution risk, management indicates current cash can fund operations into Q3 2028, supporting ongoing R&D for its RNA medicine pipeline.
WAVE Life Sciences Q2 Earnings Call Highlights
WAVE Life Sciences reported a wider net loss in Q2 2026 due to increased investment in its obesity and RNA-editing programs, despite outlining several clinical and regulatory milestones for the second half of the year. The company's revenue decreased, but it ended the quarter with substantial cash reserves, expected to fund operations into Q3 2028. Key developments include dosing for the Phase IIa obesity trial, an upcoming FDA meeting for its AATD candidate, and continued progress on its PNPLA3 liver disease program.
Wave Life Sciences (WVE) Stock Sinks As Losses Deepen And Revenue Dries Up
Wave Life Sciences (WVE) saw its stock drop by 4.3% following Q2 2026 earnings that revealed a widening net loss of US$69.4 million and a significant revenue decline of 73.9% year-over-year. Despite the company's reliance on its PRISM platform for RNA medicines and management's assurance of funding into Q3 2028, bears highlight the concentration risk, high burn rate, and execution pressure from binary clinical events. The article underscores investor concern over sustained losses and the need for successful clinical outcomes for WVE-006 and WVE-007.
Wave Life Sciences (WVE) Q2 2026 Earnings Call Transcript
Wave Life Sciences (WVE) reported Q2 2026 earnings, detailing progress in its RNAi and RNA editing pipelines, particularly for obesity (WVE-007) and liver disease (WVE-006, WVE-008). The company highlighted WVE-007's potential for fat loss without muscle degradation and announced an FDA meeting to discuss an accelerated approval pathway for WVE-006 in Alpha-1 antitrypsin deficiency. Financially, Wave reported increased operating expenses and a cash runway extending into Q3 2028, while also seeking partnerships for its Huntington's and Duchenne muscular dystrophy programs.
Wave Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update
Wave Life Sciences announced its second-quarter 2026 financial results, highlighting progress in its RNA medicine pipeline, particularly for obesity (WVE-007), alpha-1 antitrypsin deficiency (WVE-006), and PNPLA3 liver disease (WVE-008). The company initiated dosing in the Phase 2a INLIGHT trial for obesity, expects an FDA meeting for potential accelerated approval of WVE-006, and plans a CTA submission for WVE-008. Wave reported $490.6 million in cash and equivalents with an expected cash runway into Q3 2028.
Earnings Flash (WVE) Wave Life Sciences Ltd. Reports Q2 Revenue $2.3M, Vs. FactSet Est of $7.4M
Wave Life Sciences Ltd. (WVE) announced its Q2 revenue of $2.3 million, falling significantly short of the FactSet estimate of $7.4 million. This earnings flash indicates a substantial miss on revenue expectations for the company.
Press Release: Wave Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update
Wave Life Sciences has released its financial results for the second quarter of 2026 and provided a business update. The company reported on its financial performance and highlighted key developments and progress across its programs. This update offers insights into Wave Life Sciences' current operational status and financial health.
Wave Life Flat on Q2 Figures
Wave Life Sciences Ltd. announced its financial results for the second quarter ended June 30, 2026, highlighting disciplined execution across its pipeline. CEO Paul Bolno discussed progress in its INLIGHT trial for obesity with WVE-007, aiming to demonstrate its potential for fat loss and cardiometabolic benefits. The company also reported on its RNA editing program for AATD, with WVE-006 showing promise for treating both lung and liver manifestations.
WVE Looks 35.5% Overvalued on GF Value™
Wave Life Sciences Ltd (NASDAQ: WVE) is considered 35.5% overvalued according to GuruFocus' GF Value™ metric, despite its Price-to-Sales ratio being below its historical median. The company reported a significant revenue decline and continued losses in Q2 2026, though it has strong financial strength and institutional backing from premium gurus. Investors are advised to be cautious due to the company's unprofitability and inherent risks in clinical-stage biotech.
Wave Life Sciences (WVE) Reports Q2 Loss, Misses Revenue Estimates
Wave Life Sciences (WVE) reported a Q2 loss of $0.34 per share, missing the Zacks Consensus Estimate of a $0.31 loss. The company also posted revenues of $2.27 million, falling short of the consensus estimate by 73.48%. Despite these misses, the estimate revisions trend for WVE was favorable ahead of the earnings release, giving it a Zacks Rank #2 (Buy).
Wave Life Sciences Ltd earnings missed by $0.04, revenue fell short of estimates
Wave Life Sciences Ltd (NASDAQ: WVE) reported a second-quarter EPS of $-0.340, missing analyst estimates by $0.04, and revenue of $2.3M, which fell short of the $7.65M consensus. The company's stock has seen a significant decline over the past 3 and 12 months, with its financial health rated as "fair performance" by InvestingPro.
Wave Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update
Wave Life Sciences (Nasdaq: WVE) announced its second quarter 2026 financial results, highlighting significant progress in its clinical pipeline. Key updates include ongoing dosing in a Phase 2a trial for WVE-007 for obesity, with plans to initiate Phase 2 combination trials later in 2026. The company also reported positive data from its WVE-006 program for AATD, leading to an FDA meeting for potential accelerated approval, and expects to file a clinical trial application for WVE-008 for PNPLA3 liver disease.
Wave Life Sciences Ltd. Q2 2026: Revenue $2.3M, EPS $(0.34) — 10-Q Summary
Wave Life Sciences Ltd. reported Q2 2026 results with $2.3 million in revenue and a diluted loss per share of $0.34. This reflects a decrease in collaboration revenue and continued investment in research and development. Despite the quarterly decline, six-month revenue increased significantly due to a GSK collaboration milestone, and the company is advancing several clinical programs.
